Valsartan 160 mg/Amlodipine 5 mg Combination Therapy versus Amlodipine 10 mg in Hypertensive Patients with Inadequate Response to Amlodipine 5 mg Monotherapy.
Jidong Sung, Jin-Ok Jeong, Sung Uk Kwon...
https://pubmed.ncbi.nlm.nih.gov/27014353/Actively Recruiting
Led by Hospital Moinhos de Vento · Updated on 2025-01-23
8518
Participants Needed
2
Research Sites
52 weeks
Total Duration
Researchers are evaluating whether a combination pill called the polypill, alone or combined with lifestyle changes using the Stroke Riskometer app, can reduce strokes and cognitive decline in adults aged 50 to 75 years with low to moderate stroke risk. This phase III, randomized, placebo-controlled clinical trial involves 8,518 participants in Brazil over 3 years to address the high stroke burden despite current prevention methods. The study compares the polypill containing valsartan, amlodipine, and rosuvastatin with a placebo and lifestyle modification against usual care. Participants first complete a 30-day run-in phase on the active polypill before being randomly assigned to one of four groups polypill with the Stroke Riskometer, placebo with the Stroke Riskometer, polypill without the Stroke Riskometer, or placebo without it. Dosage adjustments of amlodipine are allowed for adverse events. The trial is conducted across 80 health units affiliated with 20 research centers and includes a smaller part assessing surrogate endpoints like blood pressure reduction and stroke risk scale changes over 9 months. Throughout the 3-year study, participants undergo regular assessments of stroke incidence, cognitive decline, blood pressure, cholesterol, cardiovascular risk factors, and quality of life. Researchers will also monitor adverse events and the cost of stroke treatment. Participants will be followed closely for safety and adherence, with the primary outcomes being stroke and cognitive decline rates at the end of the study period.
CONDITIONS
Polypill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE)
S
Sheila CO Martins, PhD
T
Thais L Secchi, MSc
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Hospital Moinhos de Vento
Lead Sponsor
Ministry of Health, Brazil
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 30 days
Participants take the active polypill medication during this phase before randomization.
1 visit during this period
Duration - 3 years
Participants are randomized to receive either the polypill or placebo and to either use the Stroke Riskometer app for lifestyle modification or receive usual care.
Regular visits throughout the 3 years for medication and lifestyle monitoring
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Jidong Sung, Jin-Ok Jeong, Sung Uk Kwon...
https://pubmed.ncbi.nlm.nih.gov/27014353/Valery L Feigin, Bo Norrving, Mary G George...
https://pubmed.ncbi.nlm.nih.gov/27448185/Christopher O'Regan, Ping Wu, Paul Arora...
https://pubmed.ncbi.nlm.nih.gov/18187070/Farshad Farzadfar, Mariel M Finucane, Goodarz Danaei...
https://pubmed.ncbi.nlm.nih.gov/21295847/Salim Yusuf, Eva Lonn, Prem Pais...
https://pubmed.ncbi.nlm.nih.gov/27039945/Mohammad H Forouzanfar, Patrick Liu, Gregory A Roth...
https://pubmed.ncbi.nlm.nih.gov/28097354/Priya Parmar, Rita Krishnamurthi, M Arfan Ikram...
https://pubmed.ncbi.nlm.nih.gov/25491651/Rita Krishnamurthi, Leigh Hale, Suzanne Barker-Collo...
https://pubmed.ncbi.nlm.nih.gov/30580699/Gholamreza Roshandel, Masoud Khoshnia, Hossein Poustchi...
https://pubmed.ncbi.nlm.nih.gov/31448738/Valery L Feigin, Bo Norrving, George A Mensah
https://pubmed.ncbi.nlm.nih.gov/28589034/Hospital Moinhos de Vento
Lead Sponsor
Ministry of Health, Brazil
Collaborating Sponsor